Application of the pMHC array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Brooks, Suzanne E ^a   Bonney, Stephanie A ^a   Lee, Cindy ^a,b   Publicover, Amy ^b   Khan, Ghazala ^c   Smits, Evelien L ^d   Sigurdardottir, Dagmar ^e   Arno, Matthew ^f   Li, Demin ^g   Mills, Ken I ^h   Pulford, Karen ^g   Banham, Alison H ^g   Van Tendeloo, Viggo ^d   Mufti, Ghulam J ⁱ   Rammensee, Hans Georg ^e   Elliott, Tim J ^a   Orchard, Kim H ^b   Guinn, Barbara Ann ^a,c,i  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LEUKEMIA ANTIGEN; MELAN A; MONOPHENOL MONOOXYGENASE; MUCIN 1; TUMOR ANTIGEN; WT1 PROTEIN; CELL NUCLEUS ANTIGEN; PASD1 PROTEIN, HUMAN; PEPTIDE;

ANTIBODY LABELING; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROARRAY ANALYSIS; PEPTIDE MAJOR HISTOCOMPATIBILITY COMPLEX ARRAY; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; REPRODUCIBILITY; SCANNING ELECTRON MICROSCOPY; T LYMPHOCYTE; CELL SEPARATION; IMMUNOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; METABOLISM;

ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; EPITOPES; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDES; REPRODUCIBILITY OF RESULTS;

EID: 84949454543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140483     Document Type: Article

References (68)

1. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305: 200-205. PMID: 15247469
2. Jager E, Jager D, Knuth A (2003) Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 106: 817-820. PMID: 12918057
3. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625. PMID: 16034368
4. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94-96. PMID: 8810254
5. Voss S, Skerra A (1997) Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng 10: 975-982. PMID: 9415448
6. Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, et al. (1998) Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19-specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A 95: 7568-7573. PMID: 9636190
7. Haanen JB, van Oijen MG, Tirion F, Oomen LC, Kruisbeek AM, Vyth-Dreese FA, et al. (2000) In situ detection of virus- and tumor-specific T-cell immunity. Nat Med 6: 1056-1060. PMID: 10973329
8. Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, et al. (2009) Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 6: 520-526. doi: 10.1038/nmeth.1345 PMID: 19543285
9. Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO (2003) Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol 1: E65. PMID: 14691537
10. Chen DS, Soen Y, Stuge TB, Lee PP, Weber JS, Brown PO, et al. (2005) Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2: e265. PMID: 16162034
11. Newell EW, Klein LO, Yu W, Davis MM (2009) Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods 6: 497-499. doi: 10.1038/nmeth.1344 PMID: 19543286
12. Newell EW, Sigal N, Nair N, Kidd BA, Greenberg HB, Davis MM. (2013) Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat Biotechnol 31: 623-629. doi: 10.1038/nbt.2593 PMID: 23748502
13. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM (2012) Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity 36: 142-152. doi: 10.1016/j.immuni.2012.01.002 PMID: 22265676
14. Dittmann J, Keller-Matschke K, Weinschenk T, Kratt T, Heck T, Becker HD, et al. (2005) CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol Immunother 54: 750-758. PMID: 15614528
15. Weinschenk T, Gouttefangeas C, Schirle M, Obermayr F, Walter S, Schoor O, et al. (2002) Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 62: 5818-5827. PMID: 12384544
16. Arenkov P, Kukhtin A, Gemmell A, Voloshchuk S, Chupeeva V, Mirzabekov A. (2000) Protein microchips: use for immunoassay and enzymatic reactions. Anal Biochem 278: 123-131. PMID: 10660453
17. Arnold D, Keilholz W, Schild H, Dumrese T, Stevanovic S, Rammensee HG. (1997) Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools. Eur J Biochem 249: 171-179. PMID: 9363769
18. Passoni L, Scardino A, Bertazzoli C, Gallo B, Coluccia AM, Lemonnier FA, et al. (2002) ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 99: 2100-2106. PMID: 11877285
19. Verma B, Hawkins OE, Neethling FA, Caseltine SL, Largo SR, Hildebrand WH, et al. (2010) Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties. Cancer Immunol Immunother 59: 563-573. doi: 10.1007/s00262-009-0774-8 PMID: 19779714
20. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, et al. (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70: 7569-7579. PMID: 8892876
21. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, et al. (2000) Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 60: 4845-4849. PMID: 10987296
22. Bodmer H, Ogg G, Gotch F, McMichael A (1989) Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes. Nature 342: 443-446. PMID: 2479838
23. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, et al. (1999) The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59: 5554-5559. PMID: 10554034
24. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, et al. (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183: 527-534. PMID: 8627164
25. Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, et al. (1999) Massspectrometric evaluation of HLA-A∗0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 82: 669-677. PMID: 10417764
26. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, et al. (1993) HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150: 4659-4671. PMID: 7683326
27. Mathieu MG, Knights AJ, Pawelec G, Riley CL, Wernet D, Lemonnier FA, et al. (2007) HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother 56: 1885-1895. PMID: 17487488
28. Smithgall M, Misher L, Spies G, Cheever MA, Gaiger A (2001) Identification of a novel WT1 HLAA∗ 0201-restricted CTL epitope using whole gene in vitro priming [abstract]. American Society of Hematology Meeting; December 8-11, 2001; Orlando, FL.
29. Rehermann B, Lau D, Hoofnagle JH, Chisari FV (1996) Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97: 1655-1665. PMID: 8601631
30. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, et al. (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95: 2198-2203. PMID: 10733485
31. Kast WM, Brandt RM, Sidney J, Drijfhout JW, Kubo RT, Grey HM, et al. (1994) Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 152: 3904-3912. PMID: 7511661
32. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, et al. (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160: 1750-1758. PMID: 9469433
33. Carmon L, El-Shami KM, Paz A, Pascolo S, Tzehoval E, Tirosh B, et al. (2000) Novel breast-tumorassociated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain. Int J Cancer 85: 391-397. PMID: 10652432
34. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, et al. (1995) Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci U S A 92: 8078-8082. PMID: 7644541
35. Hoff A, Bagu AC, Andre T, Roth G, Wiesmuller KH, Gückel B, et al. (2010) Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells. Cancer Immunol Immunother 59: 1379-1387. doi: 10.1007/s00262-010-0867-4 PMID: 20512327
36. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, et al. (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93: 4309-4317. PMID: 10361129
37. Benninger-Doring G, Pepperl S, Deml L, Modrow S, Wolf H, Jilg W. (1999) Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers. Virology 264: 289-297. PMID: 10562493
38. Rudolf D (2008) Efficient in vitro priming of tumor-and virus-specific CD8+ T cells with calibrated artifical APCs. PhD thesis, University of Tubingen.
39. Hill AB, Lee SP, Haurum JS, Murray N, Yao QY, Rowe M, et al. (1995) Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 181: 2221-2228. PMID: 7539044
40. Cooper CD, Liggins AP, Ait-Tahar K, Roncador G, Banham AH, Pulford K. (2006) PASD1, a DLBCLassociated cancer testis antigen and candidate for lymphoma immunotherapy. Leukemia 20: 2172-2174. PMID: 17024112
41. Zhang QJ, Lindquist Y, Levitsky V, Masucci MG (1996) Solvent exposed side chains of peptides bound to HLA A.∗1101 have similar effects on the reactivity of alloantibodies and specific TCR. Int Immunol 8: 927-938. PMID: 8671682
42. Hardwick N, Buchan S, Ingram W, Khan G, Vittes G, Rice J, et al. (2013) An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immun 13: 16. PMID: 23882161
43. Gnjatic S, Bressac-de Paillerets B, Guillet JG, Choppin J (1995) Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 25: 1638-1642. PMID: 7542198
44. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. (1997) Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 185: 1605-1617. PMID: 9151898
45. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, et al. (1996) Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88: 2450-2457. PMID: 8839835
46. Misko IS, Schmidt C, Martin N, Moss DJ, Sculley TB, Burrows S, et al. (1990) Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells. Int J Cancer 46: 399-404. PMID: 2168343
47. Walter S, Bioley G, Buhring HJ, Koch S, Wernet D, Zippelius A, et al. (2005) High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol 35: 2876-2885. PMID: 16134083
48. Whelan JA, Dunbar PR, Price DA, Purbhoo MA, Lechner F, Ogg GS, et al. (1999) Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 163: 4342-4348. PMID: 10510374
49. Apperley J, Carreras E, Gluckman E, Masszi T. ESH-EBMT Handbook on Haemopoietic Stem Cell Transplantation. 2012 revised edition.
50. Ait-Tahar K, Liggins AP, Collins GP, Campbell A, Barnardo M, Lawrie C, et al. (2009) Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br J Haematol 146: 396-407. doi: 10.1111/j.1365-2141.2009.07761.x PMID: 19552722
51. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, et al. (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180: 347-352. PMID: 7516411
52. Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, et al. (1997) Cytolytic T lymphocyte recognition of the immunodominant HLA-A∗0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 159: 2366-2374. PMID: 9278327
53. Deviren G, Gupta K, Paulaitis ME, Schneck JP (2007) Detection of antigen-specific T cells on p/MHC microarrays. J Mol Recognit 20: 32-38. PMID: 17094178
54. Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, et al. (2009) Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc 131: 9695-9703. doi: 10.1021/ja9006707 PMID: 19552409
55. Bakker AH, Hoppes R, Linnemann C, Toebes M, Rodenko B, Berkers CR, et al. (2008) Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci U S A 105: 3825-3830. doi: 10.1073/pnas.0709717105 PMID: 18308940
56. Rodenko B, Toebes M, Hadrup SR, van Esch WJ, Molenaar AM, Schumacher TN, et al. (2006) Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 1: 1120-1132. PMID: 17406393
57. Hadrup SR, Toebes M, Rodenko B, Bakker AH, Egan DA, Ovaa H, et al. (2009) High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol 524: 383-405. doi: 10.1007/978-1-59745-450-6-28 PMID: 19377960
58. Celie PH, Toebes M, Rodenko B, Ovaa H, Perrakis A, Schumacher TN. (2009) UV-induced ligand exchange in MHC class I protein crystals. J Am Chem Soc 131: 12298-12304. doi: 10.1021/ja9037559 PMID: 19655750
59. Guinn BA, Bland EA, Lodi U, Liggins AP, Tobal K, Petters S, et al. (2005) Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. Biochem Biophys Res Commun 335: 1293-1304. PMID: 16112646
60. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-3079. PMID: 7949179
61. Mason D (1998) A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today 19: 395-404. PMID: 9745202
62. Bhardwaj V, Kumar V, Geysen HM, Sercarz EE (1993) Degenerate recognition of a dissimilar antigenic peptide by myelin basic protein-reactive T cells. Implications for thymic education and autoimmunity. J Immunol 151: 5000-5010. PMID: 7691962
63. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. (2008) Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111: 236-242. PMID: 17875804
64. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, et al. (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169: 350-358. PMID: 12077264
65. Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, et al. (2014) Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 164: 366-375. doi: 10.1111/bjh.12637 PMID: 24422723
66. Guinn B, Greiner J, Schmitt M, Mills KI (2009) Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. Blood 113: 1203-1204. doi: 10.1182/blood-2008-09-178848 PMID: 19179477
67. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, et al. (2006) Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 108: 4109-4117. PMID: 16931630
68. King EV, Ottensmeier CH, Thomas GJ (2014) The immune response in HPV oropharyngeal cancer. Oncoimmunology 3: e27254. PMID: 24575385